HIVEC as an alternative option in non-muscle-invasive bladder cancer: Experiences from a high-volume center

CONCLUSION: Chemohyperthermia using HIVEC results in high recurrence-free survival and a 2-year progression-free survival rate of 98% with a bladder preservation rate of almost 80%. Comparing our data, HIVEC shows better oncological results together with better tolerability and safety making HIVEC a good alternative for patients who refuse radical cystectomy or who are ineligible for radical cystectomy.PMID:38653592 | DOI:10.1016/j.urolonc.2024.01.300

Source: Urologic Oncology - April 23, 2024 Category: Urology & Nephrology Authors: Lucas Kastner Constantin Rieger David Pfister Max Schmautz Enno Storz Axel Heidenreich Source Type: research